McKesson to Acquire Precision Medicine Group for $2.25B, Expanding Oncology Services

What happened

McKesson announced a $2.25 billion acquisition of Precision Medicine Group, aiming to expand clinical research and commercialization services in oncology and multispecialty care. The deal deepens McKesson's strategic shift toward higher-margin services, but occurs when the stock trades at ~32.6x trailing EPS and faces a revived $2.5B West Virginia opioid lawsuit. The acquisition adds to a series of tuck-in deals that have boosted Oncology & Multispecialty segment growth, which rose 32% YoY in Q2 FY26 but was partly aided by one-time gains. Management's focus on specialty platforms supports the long-term 13–16% EPS growth target, but the premium paid may pressure near-term returns. Investors should watch integration costs and whether the business delivers organic profit growth consistent with the premium valuation.

Implication

Investors should treat this deal as a continuation of McKesson's portfolio reshaping rather than a game-changer. The $2.25B price tag is manageable relative to free cash flow, but it adds integration risk and may dilute near-term returns. With the stock near $825 and a potential sell rating from our master report, the acquisition does not alter the asymmetric risk-reward, which favors trimming above $880. The key remains whether Oncology & Multispecialty can sustain organic profit growth above 13% without relying on acquisitions or one-time gains. Until evidence of that emerges, maintain a cautious stance and consider entering closer to $720 if the stock pulls back.

Thesis delta

The acquisition is consistent with the existing thesis that McKesson is shifting toward higher-margin oncology services, but it does not change the overall bearish-to-neutral stance. The deal may further inflate near-term growth metrics via acquisition contributions, while the valuation and litigation risks remain unchanged. The thesis shifts from 'potential sell' to 'hold with a negative bias' until the market digests the deal's integration and return profile.